Sisram Medical (SEHK:1696) Stock Revenue Growth Masks Sharp Margin Compression

Sisram Medical stock has been under pressure, down about 27% over the past three months, yet today’s H1 2026 earnings story is not just about the share price slide. The headline is a clear profit squeeze. Revenue edged up to US$171.4m, but adjusted net profit was only US$5.04m, and the net result swung to a small loss. For a medical aesthetics equipment and injectables business that trades on a P/E of 11.1x and pays a 4.46% dividend, the real question now is how much short term margin pain investors will accept in pursuit of its longer term growth plan.

Is Sisram Medical stock now a value opportunity at 11.1x P/E with a 4.46% yield, or just a margin story under pressure? Compare today’s share price against intrinsic value in the valuation analysis for Sisram Medical

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): US$171.4m vs. US$165.5m (up about 3.6%)
• Net Income or Loss (H1 2026 vs H1 2025): Loss of US$1.2m vs. profit of US$6.4m (moved from profit to loss)
• Basic EPS (H1 2026 vs H1 2025): US$0.0025 loss per share vs. US$0.0137 earnings per share (moved from earnings to loss)
• Gross Margin (H1 2026 vs H1 2025): 56.7% vs. 60.0% (margin compressed)

Prefer clean visuals instead of scrolling through earnings tables and dense reports? See Sisram Medical’s full financial picture with a clear view of its profit trends in the company report for Sisram Medical.

Sisram Medical bull case hinges on mix shift proof

Bulls argue that Sisram Medical is building a higher quality, more recurring business as injectables and AI supported services ramp. H1 gives some proof of concept. Injectables revenue reached US$22.2m and grew much faster than the group, and now account for about 12.9% of sales compared with 8.7% in 2025. DAXXIFY in China has shipped over 30,000 vials into roughly 500 premium clinics, and management still frames the commercial push against an RMB100m annual goal. APAC now contributes 45% of revenue, helped by launches like Soprano Titanium in Thailand. These are real milestones for the ecosystem story. However, group gross margin fell to 56.7% despite this mix shift and adjusted net margin sits at 2.9%. The higher margin, recurring engine is not yet offsetting upfront investment and North America weakness.

Bear case tests margin strain and execution risk

Bears focus on margin strain, heavy device exposure and execution risk in new products and regions. H1 margins support those concerns. Gross margin compressed from 60.0% to 56.7% and the company moved from a US$6.4m profit to a US$1.2m loss, even though revenue grew to US$171.4m. Operating expenses rose 8.5%, mainly from China injectable spending, and adjusted net margin is only 2.9%. EBD revenue of US$134m fell 2.5% and North America stayed weak, so the legacy device base is not providing the operating leverage the narrative suggests. The share price is down about 27% over 90 days, which shows the market is already reacting to these execution and profitability questions. At the same time, APAC growth of 19.1% and a 54.2% rise in injectables revenue limit the argument that the ecosystem plan is failing outright.

Compare Sisram Medical’s injectables growth, APAC expansion and margin squeeze with how the stock has traded since the H1 release, then ask whether analysts see today’s HK$2.13 price as aligned with their outlook. Track the gap between the story management is telling and what the street is pricing in through the consensus price target analysis for Sisram Medical.

Stay Ahead With Simply Wall St

Sisram Medical’s profit squeeze and fast growing injectables arm make it a stock that many investors may want to track carefully over the coming quarters. Register for free with Simply Wall St and add it to your Watchlist to keep an eye on how the share price moves against fair value and watch for a potentially more attractive entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on the key fundamental and valuation updates that matter most. Round this out by tapping into crowd wisdom through the Community so you can spot potential catalysts and risks early and stay ahead of the market.

Seeking Alternatives Beyond Sisram Medical?

Fresh stock ideas can move from quiet to flying once momentum builds, and the best entry points often go fast. Check these under the radar lists and get in early.

• Spot companies quietly building strength on solid cash flows and balance sheets by scanning the curated 277 high quality undervalued stocks before others catch the next breakout phase.
• Target resilient opportunities where risk scores stay low and fundamentals still support the story through the hand picked 291 resilient stocks with low risk scores while they remain under the radar for now.
• Ride long term income themes by focusing on businesses with sturdy payouts using the curated 433 dividend fortresses before yields drop and prices move away.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com